BUSINESS
Indian drug makers show improvement in USFDA inspection outcomes
According to USFDA data, out of 174 inspections in 2018 only 4 percent inspections are classified as OAI, attracting agency’s regulatory and administrative action such as withholding new approvals, warning letter and import alert, in contrast to 15 percent in 2017.
BUSINESS
China's Fosun to expand Gland Pharma operations in India
Frank Yao, Co-Chairman, Fosun Pharma who was in India, told Moneycontrol that the integration process of Gland Pharma with Fosun is over, and Fosun has plans to expand manufacturing footprint and add more products to the pipeline.
INDIA
Govt caps trade margins of 42 cancer drugs
Currently, 57 anti-cancer drugs are under price control as scheduled formulations.
BUSINESS
CDSCO to consider waiving off clinical trials for orphan drugs
While currently there is no definition on orphan drugs in India, medicines that are used in treatment rare diseases, with less than five lakh patients, typically fall under this category.
BUSINESS
Manipal Hospitals-Medanta deal will take more time to close, says top executive
Manipal, led by Ranjan Pai, was in race to buy Fortis Healthcare last year, but Malaysia’s IHH Healthcare outbid their rivals to buy the troubled healthcare provider.
BUSINESS
Pharma weekly wrap: USFDA lifts warning on Dr Reddy's Duvvada unit, relief after Bachupally observations
Duvvada resolution is expected to give a huge fillip to the company, as around 20% of its future ANDA (abbreviated new drug applications) filings were made from this facility.
BUSINESS
Aster DM to build budget hospitals in Gulf to meet demand from insured workers
In an exclusive interview over phone from Dubai, Moopen told Moneycontrol that insurance coverage to workers increased volumes but also put pressure on margins, as insurance companies now started pushing for steep discounts on package rates.
BUSINESS
Bharat Biotech acquires Chiron Behring Vaccines from GSK for undisclosed amount
The acquisition allows Hyderabad-headquartered Bharat Biotech to become world's largest manufacturer of rabies vaccines.
BUSINESS
USFDA Form 483 points to repeat observations at Dr Reddy's Bachupally plant
Out of 11, four are repetitive observations made by the agency in its inspection in 2017, while one observation goes even back to 2015 inspection.
BUSINESS
Laurus Labs invests over $100 million on formulation biz
In an exclusive interview, Laurus Labs CEO Satyanarayana Chava said the drug maker has invested around Rs 750-800 crore on developing products and building factories.
BUSINESS
Sun Pharma up against challenges as it builds speciality biz in US
"We committed close to a $1 billion on specialty business, we have to justify that investment and produce returns," Dilip Shanghvi said in the company's earnings call on February 12.
BUSINESS
Delhi HC sets aside govt ban on Lupin's diabetes drugs
Gluconorm-PG is a triple combination of diabetes drugs Glimepiride, Metformin, Pioglitazone, with sales of around Rs 50 crore.
BUSINESS
Sun Pharma responds to SEBI queries on super-stockist Aditya Medisales, 2004 FCCB issue
MD Dilip Shanghvi assures investors that at no point of time Sun Pharma's minority shareholders were disadvantaged in transactions with Aditya Medisales
BUSINESS
Indian pharma lobby seeks removal of India from US patent violator list
IPA has drawn the attention of USTR to the rapid progress made by India on a number of fronts, which were cited by USTR while placing India on the Priority Watch List in 2018
BUSINESS
Pharma weekly wrap: Government to regulate medical devices along the lines of drugs
The government's decision will ensure that medical devices and implants used in India are safe and tested, by bringing all these devices under Indian drug regulator Central Drugs Standard Control Organisation (CDSCO).
BUSINESS
Lupin gets 2 USFDA observations for its Goa plant
Lupin's Goa site, along with Unit 2 manufacturing plant in Pithampur, Indore are under USFDA's warning letter since November 2017.
BUSINESS
Pharma entrepreneur Jayaram Chigurupati death case shifts to Hyderabad police, mystery deepens
According to police, Rakesh Reddy allegedly killed Chigurupati over non-repayment of Rs 5.8 crore loan he had given to the latter.
BUSINESS
Maharashtra to invite tenders worth Rs 2,000 crore for Jyotiba Phule health scheme
Since inception the state government has spent around Rs 5000 crore on premiums and 52 lakh people were benefited.
BUSINESS
Cipla to continue cost cutting via portfolio rationalisation, manufacturing network review
Cipla had exited certain low margin products from the portfolio of its subsidiary Invagen in US.
BUSINESS
Lupin expects better show in Q4FY19 led by US launch of Levothyroxine, Ranolazine
Ranolazine or Renexa used in treatment of chest pain is expected to be launched in Q4 has three months marketing exclusivity. Renexa sold by Gilead Sciences had sales of $758 million.
BUSINESS
The gripping story of pharma entrepreneur Jayaram Chigurupati who lost his fortune, and life
The deal with Ranbaxy made Chigurupati overnight billionaire. Flush with cash he went on to acquire and set up at least a dozen companies.
BUSINESS
The risk of Ayushman Bharat eating into other healthcare schemes looms large
What is worrying is that the allocations for health expenditure remained flat beyond Ayushman Bharat.
BUSINESS
Union Budget 2019 spooks pharma & healthcare cos as govt overlooks their demands
Some of their demands such as bringing down the corporate tax to 25 percent and resumption of 200 percent weighted deduction on R& D were overlooked
BUSINESS
Budget 2019: Spend on PM's pet scheme Ayushman Bharat jumps 167%
Excluding the Ayushman Bharat scheme, increase in health allocation is only 6 percent.
